Richard E Overman1, Tanvi T Kartal1, Aaron J Cunningham2, Elizabeth A Fialkowski2, Bindi J Naik-Mathuria3, Sanjeev A Vasudevan3, Marcus M Malek4, Ranjeet Kalsi4, Hau D Le5, Linda Cherney Stafford5, Timothy B Lautz6, Benjamin T Many6, Rachel E Jones6, Andreana Bütter7, Jacob Davidson7, Andrew Williams7, Roshni Dasgupta8, Jana Lewis8, Misty Troutt8, Jennifer H Aldrink9, Sara A Mansfield9, Dave R Lal10, Jerry Xiao10, Rebecka L Meyers11, Scott S Short11, Erika A Newman1. 1. Division of Pediatric Surgery, Department of Surgery, C. S. Mott Children's Hospital, The University of Michigan, Ann Arbor, Michigan. 2. Department of Surgery, Division of Pediatric Surgery, Oregon Health and Science University, Portland, Oregon. 3. Department of Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas. 4. Division of Pediatric General and Thoracic Surgery, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 5. Division of Pediatric Surgery, American Family Children's Hospital, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 6. Division of Pediatric Surgery, Ann & Robert H Lurie Children's Hospital of Chicago, Northwestern University, Evanston, Illinois. 7. Division of Pediatric Surgery, Children's Hospital, London Health Sciences Centre, Western University, London, Ontario, Canada. 8. Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 9. Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio. 10. Division of Pediatric Surgery, Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, Wisconsin. 11. Division of Pediatric Surgery, Primary Children's Hospital, University of Utah, Salt Lake City, Utah.
Abstract
BACKGROUND: Image-guided percutaneous core needle biopsy (PCNB) is increasingly utilized to diagnose solid tumors. The objective of this study is to determine whether PCNB is adequate for modern biologic characterization of neuroblastoma. PROCEDURE: A multi-institutional retrospective study was performed by the Pediatric Surgical Oncology Research Collaborative on children with neuroblastoma at 12 institutions over a 3-year period. Data collected included demographics, clinical details, biopsy technique, complications, and adequacy of biopsies for cytogenetic markers utilized by the Children's Oncology Group for risk stratification. RESULTS: A total of 243 children were identified with a diagnosis of neuroblastoma: 79 (32.5%) tumor excision at diagnosis, 94 (38.7%) open incisional biopsy (IB), and 70 (28.8%) PCNB. Compared to IB, there was no significant difference in ability to accurately obtain a primary diagnosis by PCNB (95.7% vs 98.9%, P = .314) or determine MYCN copy number (92.4% vs 97.8%, P = .111). The yield for loss of heterozygosity and tumor ploidy was lower with PCNB versus IB (56.1% vs 90.9%, P < .05; and 58.0% vs. 88.5%, P < .05). Complications did not differ between groups (2.9 % vs 3.3%, P = 1.000), though the PCNB group had fewer blood transfusions and lower opioid usage. Efficacy of PCNB was improved for loss of heterozygosity when a pediatric pathologist evaluated the fresh specimen for adequacy. CONCLUSIONS: PCNB is a less invasive alternative to open biopsy for primary diagnosis and MYCN oncogene status in patients with neuroblastoma. Our data suggest that PCNB could be optimized for complete genetic analysis by standardized protocols and real-time pathology assessment of specimen quality.
BACKGROUND: Image-guided percutaneous core needle biopsy (PCNB) is increasingly utilized to diagnose solid tumors. The objective of this study is to determine whether PCNB is adequate for modern biologic characterization of neuroblastoma. PROCEDURE: A multi-institutional retrospective study was performed by the Pediatric Surgical Oncology Research Collaborative on children with neuroblastoma at 12 institutions over a 3-year period. Data collected included demographics, clinical details, biopsy technique, complications, and adequacy of biopsies for cytogenetic markers utilized by the Children's Oncology Group for risk stratification. RESULTS: A total of 243 children were identified with a diagnosis of neuroblastoma: 79 (32.5%) tumor excision at diagnosis, 94 (38.7%) open incisional biopsy (IB), and 70 (28.8%) PCNB. Compared to IB, there was no significant difference in ability to accurately obtain a primary diagnosis by PCNB (95.7% vs 98.9%, P = .314) or determine MYCN copy number (92.4% vs 97.8%, P = .111). The yield for loss of heterozygosity and tumor ploidy was lower with PCNB versus IB (56.1% vs 90.9%, P < .05; and 58.0% vs. 88.5%, P < .05). Complications did not differ between groups (2.9 % vs 3.3%, P = 1.000), though the PCNB group had fewer blood transfusions and lower opioid usage. Efficacy of PCNB was improved for loss of heterozygosity when a pediatric pathologist evaluated the fresh specimen for adequacy. CONCLUSIONS: PCNB is a less invasive alternative to open biopsy for primary diagnosis and MYCN oncogene status in patients with neuroblastoma. Our data suggest that PCNB could be optimized for complete genetic analysis by standardized protocols and real-time pathology assessment of specimen quality.
Authors: Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle Journal: Ecancermedicalscience Date: 2022-02-17
Authors: Scott S Short; Zachary J Kastenberg; Guo Wei; Alex Bondoc; Roshni Dasgupta; Greg M Tiao; Erin Watters; Todd E Heaton; Dimitra Lotakis; Michael P La Quaglia; Andrew J Murphy; Andrew M Davidoff; Sara A Mansfield; Max R Langham; Timothy B Lautz; Riccardo A Superina; Katherine C Ott; Marcus M Malek; Katrina M Morgan; Eugene S Kim; Abigail Zamora; Danny Lascano; Jonathan Roach; Joseph T Murphy; David H Rothstein; Sanjeev A Vasudevan; Richard Whitlock; Dave R Lal; Brian Hallis; Andreana Bütter; Reto M Baertschiger; Eveline Lapidus-Krol; Juan Putra; Elisabeth R Tracy; Jennifer H Aldrink; Jordan Apfeld; Hau D Le; Keon Y Park; Barrie S Rich; Richard D Glick; Elizabeth A Fialkowski; Alan F Utria; Rebecka L Meyers; Kimberly J Riehle Journal: Cancer Date: 2022-05-13 Impact factor: 6.921
Authors: Andee M Beierle; Colin H Quinn; Hooper R Markert; Adam Carr; Raoud Marayati; Laura V Bownes; Sara Claire Hutchins; Jerry E Stewart; Benjamin Hill; Michael Ohlmeyer; Nigel F Reuel; Elizabeth A Beierle Journal: ACS Omega Date: 2022-09-02